Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma

argenx’s 2015 deal with Leo Pharma for anti-inflammatory antibodies continues to pay off, though it hasn’t been disclosed by how much exactly.

Two years ago, Ghent-based argenx and Danish Leo Pharma teamed up to develop antibodies to counter inflammatory diseases in a deal totalling €105M. argenx just received its second preclinical milestone for granting Leo access to its preclinical candidate, ARGX-112, though an amount has not been disclosed.

The antibody, indicated for inflammatory skin diseases, was discovered with the biotech’s SIMPLE discovery platform. The Belgian biotech will carry out preclinical R&D on ARGX-112; once it hits the clinic, Leo will take over. Under the terms of the deal, the pharma holds the option to exclusive global licensing.

Image via Copula /

Previous post

UK Biotech Scores £2M in Series A to Boost its Next-generation Antibodies

Next post

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Let's Continue The Conversation

Feel free to send us comments about this article to and/or comment on that article on social media.